Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATRA
  • CUSIP: N/A
  • Web:
  • Market Cap: $414.8 million
  • Outstanding Shares: 29,089,000
Average Prices:
  • 50 Day Moving Avg: $16.14
  • 200 Day Moving Avg: $16.86
  • 52 Week Range: $12.45 - $25.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.62
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $8.01 per share
  • Price / Book: 1.78
  • EBIDTA: ($89,770,000.00)
  • Return on Equity: -27.80%
  • Return on Assets: -26.80%
  • Current Ratio: 20.63%
  • Quick Ratio: 20.63%
  • Average Volume: 302,835 shs.
  • Beta: 1.43
  • Short Ratio: 11.97

Frequently Asked Questions for Atara Biotherapeutics (NASDAQ:ATRA)

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) posted its quarterly earnings results on Thursday, March, 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.98) by $0.35. View Atara Biotherapeutics' Earnings History.

Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2017?

5 analysts have issued 1 year price targets for Atara Biotherapeutics' stock. Their predictions range from $10.00 to $47.00. On average, they expect Atara Biotherapeutics' stock price to reach $24.00 in the next year. View Analyst Ratings for Atara Biotherapeutics.

What are analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (5/9/2017)
  • 2. Canaccord Genuity analysts commented, "Jounce announced initiation of the Phase 2 portion of the ICONIC study of JTX-2011." (4/21/2017)

Are investors shorting Atara Biotherapeutics?

Atara Biotherapeutics saw a increase in short interest in April. As of April 28th, there was short interest totalling 5,027,609 shares, an increase of 30.9% from the April 13th total of 3,841,078 shares. Based on an average daily trading volume, of 330,149 shares, the days-to-cover ratio is presently 15.2 days. Approximately 27.6% of the shares of the stock are sold short.

Who are some of Atara Biotherapeutics' key competitors?

Who owns Atara Biotherapeutics stock?

Atara Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baupost Group LLC MA (18.42%), Redmile Group LLC (9.39%), FMR LLC (0.00%), Eagle Asset Management Inc. (4.36%), Neuberger Berman Group LLC (0.00%) and Vanguard Group Inc. (0.00%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Eric Dobmeier, Gad Soffer, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark. View Institutional Ownership Trends for Atara Biotherapeutics.

Who sold Atara Biotherapeutics stock? Who is selling Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, Credit Suisse AG, SG Americas Securities LLC, TIAA CREF Investment Management LLC, ProShare Advisors LLC, Alliancebernstein L.P. and Nationwide Fund Advisors. Company insiders that have sold Atara Biotherapeutics stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Gad Soffer, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.

Who bought Atara Biotherapeutics stock? Who is buying Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Goldman Sachs Group Inc., Eagle Asset Management Inc., Camber Capital Management LLC, Morgan Stanley, Neuberger Berman Group LLC, Vanguard Group Inc. and Citadel Advisors LLC. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy Atara Biotherapeutics stock?

Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Atara Biotherapeutics stock cost?

One share of Atara Biotherapeutics stock can currently be purchased for approximately $14.25.

Analyst Ratings

Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (?)
Ratings Breakdown: 2 Sell Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $24.00 (68.42% upside)

Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/21/2017Canaccord GenuityReiterated RatingBuy$47.00MediumView Rating Details
3/16/2017Citigroup IncSet Price TargetSell$10.00HighView Rating Details
12/12/2016Jefferies Group LLCSet Price TargetBuy$23.00N/AView Rating Details
9/15/2016Goldman Sachs Group IncDowngradeNeutral -> Sell$23.00 -> $16.00N/AView Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$40.00 -> $34.00N/AView Rating Details
12/15/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)
Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Earnings History by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/201712/31/2016($0.98)($0.63)ViewN/AView Earnings Details
11/4/2016Q3 2016($0.79)($0.88)ViewN/AView Earnings Details
8/8/2016Q2($0.61)($0.66)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
3/3/2016Q4 2015($0.48)($0.75)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.42)($0.43)ViewN/AView Earnings Details
2/26/2015Q4 2014($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)
2017 EPS Consensus Estimate: ($3.71)
2018 EPS Consensus Estimate: ($3.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.78)($0.75)($0.77)
Q2 20172($0.92)($0.78)($0.85)
Q3 20172($1.12)($0.82)($0.97)
Q4 20172($1.37)($0.88)($1.13)
Q1 20181($0.90)($0.90)($0.90)
Q2 20181($0.91)($0.91)($0.91)
Q3 20181($0.93)($0.93)($0.93)
Q4 20181($0.84)($0.84)($0.84)
(Data provided by Zacks Investment Research)


Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Ownership Percentage: 16.10%
Institutional Ownership Percentage: 77.48%
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Isaac E CiechanoverCEOSell4,800$14.91$71,568.00View SEC Filing  
5/16/2017Carol Giltner GallagherDirectorSell1,184$15.25$18,056.00View SEC Filing  
5/16/2017Gad SofferEVPSell12,674$15.16$192,137.84View SEC Filing  
5/16/2017John McgrathCFOSell4,000$15.11$60,440.00View SEC Filing  
4/26/2017Isaac E CiechanoverCEOSell7,200$17.56$126,432.00View SEC Filing  
4/25/2017Isaac E CiechanoverCEOSell3,600$17.33$62,388.00View SEC Filing  
4/17/2017Christopher HaqqEVPSell6,000$17.28$103,680.00View SEC Filing  
4/11/2017Isaac E CiechanoverCEOSell7,200$17.03$122,616.00View SEC Filing  
3/28/2017Isaac E CiechanoverCEOSell16,000$20.06$320,960.00View SEC Filing  
3/23/2017John McgrathCFOSell14,000$20.65$289,100.00View SEC Filing  
3/17/2017Isaac E CiechanoverCEOSell30,800$19.38$596,904.00View SEC Filing  
3/10/2017Gad SofferEVPSell2,500$20.00$50,000.00View SEC Filing  
3/10/2017John McgrathCFOSell24,000$20.00$480,000.00View SEC Filing  
2/21/2017John McgrathCFOSell9,000$15.14$136,260.00View SEC Filing  
2/16/2017Carol Giltner GallagherDirectorSell1,183$16.10$19,046.30View SEC Filing  
2/16/2017Isaac E CiechanoverCEOSell4,800$15.56$74,688.00View SEC Filing  
2/16/2017Mitchall G. ClarkEVPSell3,059$15.96$48,821.64View SEC Filing  
2/15/2017Christopher HaqqEVPSell7,604$15.49$117,785.96View SEC Filing  
2/10/2017Gad SofferEVPSell6,274$15.47$97,058.78View SEC Filing  
2/9/2017Christopher HaqqEVPSell13,975$15.46$216,053.50View SEC Filing  
2/3/2017Isaac E CiechanoverCEOSell4,800$13.66$65,568.00View SEC Filing  
1/18/2017Isaac E CiechanoverCEOSell6,000$14.24$85,440.00View SEC Filing  
1/17/2017Christopher HaqqEVPSell6,000$14.27$85,620.00View SEC Filing  
1/6/2017Isaac E CiechanoverCEOSell8,400$16.89$141,876.00View SEC Filing  
12/23/2016Isaac E CiechanoverCEOSell4,800$15.22$73,056.00View SEC Filing  
12/15/2016Christopher HaqqInsiderSell6,000$15.40$92,400.00View SEC Filing  
12/7/2016Isaac E CiechanoverCEOSell7,200$17.93$129,096.00View SEC Filing  
11/23/2016Isaac E CiechanoverCEOSell12,000$18.34$220,080.00View SEC Filing  
11/22/2016Isaac E CiechanoverCEOSell8,400$18.21$152,964.00View SEC Filing  
11/16/2016Carol Giltner GallagherDirectorSell1,184$19.35$22,910.40View SEC Filing  
11/16/2016Gad SofferCOOSell16,718$20.00$334,360.00View SEC Filing  
11/16/2016Mitchall G ClarkInsiderSell2,995$19.53$58,492.35View SEC Filing  
11/14/2016Gad SofferCOOSell9,582$20.55$196,910.10View SEC Filing  
11/11/2016John McgrathCFOSell5,000$19.84$99,200.00View SEC Filing  
10/27/2016Isaac E CiechanoverCEOSell4,800$13.81$66,288.00View SEC Filing  
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.00View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Atara Biotherapeutics (NASDAQ:ATRA)
Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
DateHeadline logoAtara Biotherapeutics to Present at Three Upcoming Investor Conferences - May 24 at 10:27 AM logoAtara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 4,800 Shares - May 19 at 8:28 PM logoCarol Giltner Gallagher Sells 1,184 Shares of Atara Biotherapeutics Inc (ATRA) Stock - May 17 at 8:34 PM logoAtara Biotherapeutics Inc (ATRA) CFO John Mcgrath Sells 4,000 Shares - May 17 at 8:11 PM logoAtara Biotherapeutics Inc (ATRA) EVP Sells $192,137.84 in Stock - May 17 at 7:47 PM logoZacks: Brokerages Anticipate Atara Biotherapeutics Inc (ATRA) to Announce -$0.92 Earnings Per Share - May 15 at 2:22 PM logoAtara Biotherapeutics Inc (ATRA) Short Interest Update - May 13 at 7:02 AM logoAtara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 10 at 8:53 PM logoAtara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team - May 10 at 9:04 AM logoZacks Investment Research Downgrades Atara Biotherapeutics Inc (ATRA) to Sell - May 9 at 11:02 PM logoAtara Biotherapeutics reports 1Q loss - May 5 at 3:44 PM logoAtara Biotherapeutics Inc (ATRA) Receives Average Rating of "Hold" from Brokerages - May 5 at 8:22 AM logoAtara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights - May 4 at 8:48 PM logoAtara Biotherapeutics (ATRA) Earns Coverage Optimism Score of 0.23 - May 3 at 7:28 PM logoAtara Biotherapeutics Inc (ATRA) Set to Announce Earnings on Wednesday - May 1 at 12:23 PM logoAtara Biotherapeutics (ATRA) Getting Somewhat Critical Media Coverage, Analysis Shows - April 30 at 11:57 AM logoAtara Biotherapeutics (ATRA) Given Daily Coverage Optimism Rating of -0.07 - April 27 at 9:30 AM logoInsider Selling: Atara Biotherapeutics Inc (ATRA) CEO Sells 3,600 Shares of Stock - April 26 at 11:40 PM logoAtara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 7,200 Shares - April 26 at 11:36 PM logo Analysts Anticipate Atara Biotherapeutics Inc (ATRA) Will Post Earnings of -$0.76 Per Share - April 24 at 9:22 PM logoAtara Biotherapeutics (ATRA) Given Daily News Impact Rating of 0.26 - April 24 at 5:20 PM logoATARA Biotherapeutics (ATRA) Enters Pact With Merck (MRK) to Evaluate KEYTRUDA Combo with ATA129 in NPC - April 22 at 10:28 AM logoAtara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) - April 21 at 3:45 PM logoBiotech Movers: XBiotech, Atara, Bellicum - April 21 at 3:45 PM logoAtara Biotherapeutics (ATRA) Earns Daily Coverage Optimism Score of 0.17 - April 21 at 10:49 AM logoATRA Gains After-hours, ONTX Slumps, XBIT Disappointed, BPMX On Watch - April 21 at 1:48 AM logoAtara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 - April 20 at 8:47 PM logoAtara Biotherapeutics shares rise on MS drug study results - April 20 at 8:47 PM logoAtara Biotherapeutics Inc (ATRA) Short Interest Up 1.6% in March - April 20 at 5:57 PM logoAtara Biotherapeutics Inc (ATRA) EVP Sells $103,680.00 in Stock - April 19 at 8:23 PM logoAtara Biotherapeutics (ATRA) Receives Media Sentiment Rating of 0.31 - April 17 at 2:06 PM logoInsider Selling: Atara Biotherapeutics Inc (ATRA) CEO Sells 7,200 Shares of Stock - April 12 at 8:09 PM logoAtara Biotherapeutics Inc (ATRA) Given Average Recommendation of "Hold" by Analysts - April 10 at 8:54 AM logoAtara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer - April 3 at 4:05 PM logoIsaac E. Ciechanover Sells 16,000 Shares of Atara Biotherapeutics Inc (ATRA) Stock - March 28 at 10:28 PM logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and - March 28 at 11:22 AM logoJohn Mcgrath Sells 14,000 Shares of Atara Biotherapeutics Inc (ATRA) Stock - March 24 at 10:08 AM logoAtara Biotherapeutics Inc (ATRA) CEO Sells $596,904.00 in Stock - March 20 at 7:52 PM logoATARA Biotherapeutics (ATRA) to Present Interim Results from Phase 1 Trial of Autologous Version of ATA188 in Patients with Progressive MS - March 17 at 9:21 PM logoATARA BIOTHERAPEUTICS, INC. Financials - March 14 at 3:37 PM logoAtara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights - March 9 at 9:17 PM logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a - March 9 at 9:17 PM logoTracking Seth Klarman's Baupost Group Holdings - Q4 2016 Update - February 16 at 8:35 AM logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers - February 10 at 9:12 PM logoATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - February 8 at 3:34 PM logoAtara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference - January 4 at 3:49 PM logoReimbursement Discussions with Health Technology Assessment Agencies Being Conducted in Parallel - January 3 at 8:39 AM logo8:01 am Atara Biotherapeutics reaches agreement with FDA on design of phase 3 Trials for Allogeneic Epstein-Barr Virus -Specific Cytotoxic T Lymphocytes to 'support potential approval' in two separate indications - December 12 at 8:52 PM logoATARA Biotherapeutics (ATRA) Says Agreement Reached with FDA on Design of Phase 3 Trials for ATA 129 - - December 12 at 8:23 AM logoAtara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se - December 12 at 8:23 AM



Atara Biotherapeutics (ATRA) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff